Zenrelia™ Enquiries
Use the form below to request contact from an Elanco team member.
The information you submit on this page will be used by Elanco to facilitate your request, subscribe you to our email communications and to update our customer relationship database. For more information about how Elanco will manage your Personal Data, please view our privacy notice.
Back to normal
Zenrelia (ilunocitinib) gets nearly 50% more itchy dogs back to normal than Apoquel® (oclacitinib)1††
Once daily dosing
Simple, consistent dosing from the start2
Itch control
Zenrelia delivers 24-hour itch relief1,3
Safety profile
Safety profile comparable to Apoquel1
Value
Zenrelia’s price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs.‡
†† 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2)1
- Forster S et al. Vet Dermatol 2025; 00:1-10; DOI: 10.1111/vde.13319.
- Zenrelia™ Summary of Product Characteristics.
- Unpublished data: Owner Pruritus Assessment (PVAS) form.
